Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

BACKGROUND: Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker for progression-free and overall survival in chronic lymphocytic leukaemia. But such deep responses are also associated with severe immuno-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauthier, Martin, Durrieu, Françoise, Martin, Elodie, Peres, Michael, Vergez, François, Filleron, Thomas, Obéric, Lucie, Bijou, Fontanet, Quillet Mary, Anne, Ysebaert, Loic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694602/
https://www.ncbi.nlm.nih.gov/pubmed/31412798
http://dx.doi.org/10.1186/s12885-019-5971-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694602/
https://www.ncbi.nlm.nih.gov/pubmed/31412798
http://dx.doi.org/10.1186/s12885-019-5971-z

Ejemplares similares